Punicalagin inhibited proliferation, invasion and angiogenesis of osteosarcoma through suppression of NF‑κB signaling

Huang,Tao; Zhang,Xin; Wang,Haipeng

doi:10.3892/mmr.2020.11304

Punicalagin inhibited proliferation, invasion and angiogenesis of osteosarcoma through suppression of NF‑κB signaling

Authors:
- Tao Huang
- Xin Zhang
- Haipeng Wang
View Affiliations

Affiliations: Department of Orthopedic Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi'an, Shaanxi 710038, P.R. China
Published online on: July 6, 2020 https://doi.org/10.3892/mmr.2020.11304
Pages: 2386-2394
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common primary malignant bone tumor among children and young people and is associated with poor prognosis. Punicalagin is an antioxidant ellagitannin found in pomegranate juice with known antiproliferation and anti‑angiogenesis properties. However, the antitumor effect of punicalagin on osteosarcoma requires further investigation. In the present study, the inhibitory effect of punicalagin on proliferation and invasion was evaluated in one human osteoblast cell line (hFOB1.19) and three human osteosarcoma cell lines (U2OS, MG63 and SaOS2). The cancer cell apoptosis ratio was determined using flow cytometry. NF‑κB signaling in these cells was also evaluated using western blotting analysis. A subcutaneous tumor xenograft model was initiated to study the efficacy of punicalagin on osteosarcoma development and angiogenesis in vivo. Punicalagin treatment significantly decreased osteosarcoma cell proliferation and increased apoptosis. In addition, the invasion potential of these cells in a transwell assay was also dramatically suppressed in osteosarcoma cells. Punicalagin not only induced the degradation of IκBα but also the nuclear translocation of p65, suggesting the attenuation of NF‑κB signaling pathway following treatment. Moreover, punicalagin markedly downregulated interleukin (IL)‑6 and IL‑8 levels, which was consistent with the inhibition of NF‑κB signaling. An NF‑κB activator could reverse these effects. Using a tumor xenograft mouse model, it was demonstrated that punicalagin exposure inhibited osteosarcoma growth and angiogenesis in vivo. These observations confirmed the suppressive effect of punicalagin against osteosarcoma malignancies. The underlying molecular mechanisms may include inhibition of the NF‑κB signaling pathway.

View Figures

View References

1	Damron TA, Ward WG and Stewart A: Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National cancer data base report. Clin Orthop Relat Res. 459:40–47. 2007. View Article : Google Scholar : PubMed/NCBI
2	Anderson ME: Update on survival in osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
3	Geller DS and Gorlick R: Osteosarcoma: A review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
4	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma (M)//. Jaffe N, Bruland OS and Bielack S: Pediatric and adolescent osteosarcoma Boston, MA: Springer US; pp. 3–13. 2010
5	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
6	Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, et al: Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon Alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 33:2279–2287. 2015. View Article : Google Scholar : PubMed/NCBI
7	Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach HP and Wang C: Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med. 15:682–689. 2009. View Article : Google Scholar : PubMed/NCBI
8	Avnet S, Di Pompo G, Chano T, Errani C, Ibrahim-Hashim A, Gillie RJ, Donati DM and Baldini N: Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation. Int J Cancer. 140:1331–1345. 2017. View Article : Google Scholar : PubMed/NCBI
9	Mongre RK, Sodhi SS, Ghosh M, Kim JH, Kim N, Sharma N and Jeong DK: A new paradigm to mitigate osteosarcoma by regulation of MicroRNAs and suppression of the NF-κB signaling cascade. Dev Reprod. 18:197–212. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, et al: Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 104:749–763. 2012. View Article : Google Scholar : PubMed/NCBI
11	Testa JR and Tsichlis PN: AKT signaling in normal and malignant cells. Oncogene. 24:7391–7393. 2005. View Article : Google Scholar : PubMed/NCBI
12	Liu T, Zhang L, Joo D and Sun SC: NF-κB signaling in inflammation. Signal Transduct Target Ther. 2:170232017. View Article : Google Scholar : PubMed/NCBI
13	Germano G, Allavena P and Mantovani A: Cytokines as a key component of cancer-related inflammation. Cytokine. 43:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
14	Peng N, Gao S, Guo X, Wang G, Cheng C, Li M and Liu K: Silencing of VEGF inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT signaling pathway. Am J Transl Res. 8:10052016.PubMed/NCBI
15	Mirabello L, Troisi RJ and Savage SA: International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
16	Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, et al: Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nat Commun. 8:159362017. View Article : Google Scholar : PubMed/NCBI
17	Zhang B and Zhang Y, Li R, Li J, Lu X and Zhang Y: The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: A network meta-analysis. J Orthop Surg Res. 15:512020. View Article : Google Scholar : PubMed/NCBI
18	Block G, Patterson B and Subar A: Fruit, vegetables, and cancer prevention: A review of the epidemiological evidence. Nutr Cancer. 18:1–29. 1992. View Article : Google Scholar : PubMed/NCBI
19	Tang J, Li B, Hong S, Liu C, Min J, Hu M, Li Y, Liu Y and Hong L: Punicalagin suppresses the proliferation and invasion of cervical cancer cells through inhibition of the β-catenin pathway. Mol Med Rep. 16:1439–1444. 2017. View Article : Google Scholar : PubMed/NCBI
20	Tang JM, Min J, Li BS, Hong SS, Liu C, Hu M, Li Y, Yang J and Hong L: Therapeutic effects of punicalagin against ovarian carcinoma cells in association with β-Catenin signaling inhibition. Int J Gynecol Cancer. 26:1557–1563. 2016. View Article : Google Scholar : PubMed/NCBI
21	Omar U, Aloqbi A, Yousr M and Howell NK: Effect of punicalagin on human colon cancer caco-cells. Malaysian J Nutri. 22:125–136. 2016.
22	Li Y, Yang F, Zheng W, Hu M, Wang J, Ma S, Deng Y, Luo Y, Ye T and Yin W: Punica granatum (pomegranate) leaves extract induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in non-small cell lung cancer in vitro. Biomed Pharmacother. 80:227–235. 2016. View Article : Google Scholar : PubMed/NCBI
23	Aloqbi A, Omar U, Yousr M, Grace M, Lila MA and Howell N: Antioxidant activity of pomegranate juice and punicalagin. Nat Sci. 8:235–246. 2016.
24	Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, Hingorani L and Derendorf H: Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum L.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem. 54:8956–8961. 2006. View Article : Google Scholar : PubMed/NCBI
25	Vora A, Londhe V and Pandita N: Herbosomes enhance the in vivo antioxidant activity and bioavailability of punicalagins from standardized pomegranate extract. J Funct Foods. 12:540–548. 2015. View Article : Google Scholar
26	Seeram NP, Lee R and Heber D: Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta. 348:63–68. 2004. View Article : Google Scholar : PubMed/NCBI
27	Cerdá B, Espín JC, Parra S, Martínez P and Tomás-Barberán FA: The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr. 43:205–220. 2004. View Article : Google Scholar : PubMed/NCBI
28	Cerdá B, Llorach R, Cerón JJ, Espín JC and Tomás-Barberán FA: Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr. 42:18–28. 2003. View Article : Google Scholar : PubMed/NCBI
29	Chu G, Zhang W, Chen M, Yang H and Yuan Z: Punicalagin inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK signaling pathways. Int J Clin Exp Med. 11:6571–6582. 2018.
30	Tang J, Liu C, Min J, Hu M, Li Y and Hong L: Potential therapeutic role of punicalagin against mechanical-trauma-induced stress urinary incontinence via upregulation of Nrf2 and TGF-β1 signaling. Int Urogynecol J. 28:947–955. 2017. View Article : Google Scholar : PubMed/NCBI
31	Iwatake M, Okamoto K, Tanaka T and Tsukuba T: Punicalagin attenuates osteoclast differentiation by impairing NFATc1 expression and blocking Akt-and JNK-dependent pathways. Mol Cell Biochem. 407:161–172. 2015. View Article : Google Scholar : PubMed/NCBI
32	Adams LS, Seeram NP, Aggarwal BB, Takada Y, Sand D and Heber D: Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem. 54:980–985. 2006. View Article : Google Scholar : PubMed/NCBI
33	Kim YE, Hwang CJ, Lee HP, Kim CS, Son DJ, Ham YW, Hellström M, Han SB, Kim HS, Park EK and Hong JT: Inhibitory effect of punicalagin on lipopolysaccharide-induced neuroinflammation, oxidative stress and memory impairment via inhibition of nuclear factor-kappaB. Neuropharmacology. 117:21–32. 2017. View Article : Google Scholar : PubMed/NCBI
34	Naugler WE and Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 18:19–26. 2008. View Article : Google Scholar : PubMed/NCBI
35	Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, Carr RE, Oikawa T and Lansky EP: Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Angiogenesis. 6:121–128. 2003. View Article : Google Scholar : PubMed/NCBI
36	Bakkar N and Guttridge DC: NF-kappaB signaling: A tale of two pathways in skeletal myogenesis. Physiol Rev. 90:495–511. 2010. View Article : Google Scholar : PubMed/NCBI
37	Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M, Acharyya S, Rudnicki MA, Hollenbach AD and Guttridge DC: IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol. 180:787–802. 2008. View Article : Google Scholar : PubMed/NCBI
38	Londhe P, Yu PY, Ijiri Y, Ladner KJ, Fenger JM, London C, Houghton PJ and Guttridge DC: Classical NF-κB metabolically reprograms sarcoma cells through regulation of hexokinase 2. Front Oncol. 8:1042018. View Article : Google Scholar : PubMed/NCBI
39	Gong T, Su X, Xia Q, Wang J and Kan S: Expression of NF-κB and PTEN in osteosarcoma and its clinical significance. Oncol Lett. 14:6744–6748. 2017.PubMed/NCBI
40	Liao CL, Lin JH, Lien JC, Hsu SC, Chueh FS, Yu CC, Wu PP, Huang YP, Lin JG and Chung JG: The crude extract of Corni Fructus inhibits the migration and invasion of U-2 OS human osteosarcoma cells through the inhibition of matrix metalloproteinase-2/-9 by MAPK signaling. Environ Toxicol. 30:53–63. 2015. View Article : Google Scholar : PubMed/NCBI
41	Pan PJ, Tsai JJ and Liu YC: Amentoflavone inhibits metastatic potential through suppression of ERK/NF-κB activation in osteosarcoma U2OS cells. Anticancer Res. 37:4911–4918. 2017.PubMed/NCBI
42	Hoesel B and Schmid JA: The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 12:862013. View Article : Google Scholar : PubMed/NCBI
43	Lv F, Song LJ, Wang XH, Qiu F and Li XF: The role of Act1, a NF-κB-activating protein, in IL-6 and IL-8 levels induced by IL-17 stimulation in SW982 cells. Pharm Biol. 51:1444–1450. 2013. View Article : Google Scholar : PubMed/NCBI
44	Karin M: NF-κB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 1:a0001412009. View Article : Google Scholar : PubMed/NCBI
45	Sparmann A and Bar-Sagi D: Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 6:447–458. 2004. View Article : Google Scholar : PubMed/NCBI
46	Syed DN, Chamcheu JC, Adhami VM and Mukhtar H: Pomegranate extracts and cancer prevention: Molecular and cellular activities. Anticancer Agents Med Chem. 13:1149–1161. 2013. View Article : Google Scholar : PubMed/NCBI